UroGen Pharma Earnings Call Highlights ZUSDURI Surge

Urogen Pharma ((URGN)) has held its Q1 earnings call. Read on for the main highlights of the call.

UroGen Pharma’s latest earnings call struck a cautiously optimistic tone as management highlighted surging revenue from new bladder cancer therapy ZUSDURI alongside improving commercial metrics and a strengthening pipeline. Executives balanced this momentum against elevated launch-related spending, ongoing net losses and still-limited physician penetration, underscoring both the opportunity and execution risk ahead.

Strong Q1 Revenue Growth

UroGen reported total revenue of $51.0 million for Q1 2026, up sharply from $20.3 million a year earlier, marking a 152% year-over-year increase. Management credited the performance primarily to the commercial ramp of ZUSDURI and continued contributions from legacy product JELMYTO.

ZUSDURI Early Launch Momentum

ZUSDURI generated $29.2 million in Q1 2026, more than doubling sequentially and signaling strong early uptake in its target market. Unique prescribers rose to 256 from 102 at year-end, while repeat prescribers tripled to 103, suggesting growing confidence and repeat use among physicians.

Improving Conversion and Channel Mix

The company shortened the time from patient enrollment to treatment start to roughly 30–35 days in Q1, down from 45–60 days in Q4, and is targeting a 2–3 week steady state. Channel mix shifted from heavily hospital-weighted to a roughly 50/50 split with community settings, a key shift given that about 70% of the market resides in community practices.

JELMYTO Stability and Outlook

JELMYTO delivered $21.7 million in Q1 2026 revenue, with management emphasizing its stable and predictable demand profile. Full-year 2026 guidance for JELMYTO net product revenue remains at $97–$101 million, implying modest 3%–7% year-over-year growth from this established franchise.

Pipeline Progress and Regulatory Milestones

Lead pipeline candidate UGN-103 achieved a 77.8% complete response rate at three months in the Phase III UTOPIA trial, supporting plans for an NDA filing in the second half of 2026 and a potential approval in 2027. UGN-104’s Phase III trial is expected to complete enrollment by the end of 2026, while UGN-501 is slated to enter Phase I testing in NMIBC following an IND filing in the second quarter.

Clinical Durability and Published Data

ENVISION data for ZUSDURI showed about an 80% complete response rate at three months and a 72% event-free probability at 24 months using Kaplan–Meier analysis. Median duration of response has not yet been reached at a median follow-up of 23.7 months, and results have been published in the Journal of Urology with additional presentation planned at a major urology meeting.

Stronger Balance Sheet and Lower R&D Spend

UroGen ended the quarter with $140.3 million in cash, cash equivalents and marketable securities, supported by a term loan refinancing that extends its runway. Research and development expenses fell to $15.6 million from $19.9 million in the prior-year quarter, a 22% decline tied to prior-period items and program timing.

Narrowing Net Loss but No Profit Yet

The company’s net loss shrank to $23.6 million, or $0.47 per share, from $43.8 million, or $0.92 per share, a year earlier, reflecting higher revenue and lower R&D. Even so, management acknowledged that UroGen remains unprofitable and is guiding for full-year operating expenses of $240–$250 million.

High SG&A and Launch Investment

Selling, general and administrative expenses climbed to $51.5 million in Q1 2026 from $35.0 million a year ago as UroGen scaled its commercial infrastructure. The increase was driven by ZUSDURI launch activities, sales force expansion, brand marketing and one-time advisory and refinancing fees, with management suggesting Q1 should represent the peak SG&A quarter of the year.

Limited Visibility on ZUSDURI Trajectory

Despite strong early indicators, management declined to issue formal 2026 sales guidance for ZUSDURI, citing the inherent uncertainty of early launch dynamics. This leaves investors with robust but still short-term metrics and underscores the difficulty of forecasting near-term revenue, even as internal targets remain ambitious.

Early Penetration vs Long-Term Potential

UroGen estimates a long-term addressable base of about 8,500 health care providers for ZUSDURI, highlighting substantial room for expansion beyond the 256 current prescribers. The gap underscores both the early stage of adoption and the scale of commercial effort required to reach broad penetration in community and hospital settings.

Modest JELMYTO Growth and Patient-Finding Hurdles

Management expects JELMYTO to grow in the low single digits, consistent with its $97–$101 million revenue outlook for 2026. Growth remains constrained by the difficulty physicians face in identifying eligible patients and the sporadic presentation of cases, which limits frequency of use per provider.

Pricing Perception and Reimbursement Dynamics

Although ZUSDURI now enjoys access for more than 95% of covered lives and a dedicated billing code, management noted lingering perception challenges around its roughly $130,000 price. Some stakeholders compare it with pricier high-risk therapies, and cost sensitivity remains an important factor in adoption despite generally favorable reimbursement.

Higher Interest Costs from Refinancing

The company’s recent refinancing with an additional $75 million borrowing modestly raised its interest expense and financing costs in the quarter. While the transaction strengthens liquidity and supports the launch, it also increases leverage, adding another consideration for investors tracking UroGen’s path to profitability.

Guidance and Outlook

Management reaffirmed 2026 guidance calling for JELMYTO net product revenue of $97–$101 million, representing 3%–7% growth, while refraining from setting formal ZUSDURI sales targets for the year. Full-year operating expenses are projected at $240–$250 million, and leadership emphasized strong commercial KPIs, broad payer access and a multibillion-dollar addressable market as they position ZUSDURI for potential peak revenue above $1 billion.

UroGen’s earnings call painted a picture of a company transitioning from a single-product base to a broader oncology franchise built around ZUSDURI and a deepening pipeline. For investors, the story hinges on whether robust early launch momentum and pipeline successes can outpace rising costs and execution risk as the company pushes toward scale and, eventually, profitability.